5 Key Takeaways

• 1

  Partnerships in biopharma are evolving to address increasing complexity, requiring specialized expertise across various development stages.

• 2

  Big pharma is increasingly partnering with Chinese companies, reflecting improved standards in Chinese R&D and significant deal values.

• 3

  Smaller biotech firms are central to early development, allowing larger companies to engage later through licensing and strategic support.

• 4

  Partnership models are shifting from traditional customer-supplier relationships to more integrated, collaborative approaches.

• 5

  Companies are prioritizing organizational fit and cultural alignment in partner selection to enhance long-term collaboration success.